February 03, 2017
A Delaware federal judge ruled Thursday that AstraZeneca's patents covering its $3.5 billion diabetes drugs Onglyza and Kombiglyze XR were not invalid for being obvious, though he denied the pharmaceutical company's request for attorneys' fees in its suit against generic drug makers.
September 20, 2016
A Delaware federal judge has ruled that AstraZeneca's patent infringement suit against Wockhardt over planned generic versions of AstraZeneca diabetes drugs can proceed, even though Wockhardt last month told regulators it won't seek approval until the patent expires.